Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00576095 · ClinicalTrials.gov registry record
Clinical and Biological Characteristics of Psychotic Depression
A clinical trial of Depression and Depressive Disorder, Major, sponsored by Stanford University.
- Completed
- Registry status
- 73
- Enrollment target
- 1
- Study location
NCT00576095: Completed study of Depression and Depressive Disorder, Major, sponsored by Stanford University.
NCT00576095 is a study of Depression and Depressive Disorder, Major that has completed, run by Stanford University. The registered enrollment target is 73 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00576095, a study of Depression and Depressive Disorder, Major, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to investigate the relationships among findings in structural and functional neuroimaging, cognitive testing and HPA (hypothalamic-pituitary-adrenal) axis dysregulation in psychotic depression.
Primary Outcome
Hourly serum cortisol
Conditions Studied
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2005-08 |
| Est. Completion | 2012-06 |
What the finished NCT00576095 record still lists
NCT00576095 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 0 interventions.
NCT00576095 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00576095 about?
NCT00576095 is a clinical study titled "Clinical and Biological Characteristics of Psychotic Depression". The primary objective of this study is to investigate the relationships among findings in structural and functional neuroimaging, cognitive testing and HPA (hypothalamic-pituitary-adrenal) axis dysregulation in psychotic depression.
What is the current status of trial NCT00576095?
This trial is currently completed. The enrollment target is 73 participants. The study started on 2005-08. Estimated completion is 2012-06.
What conditions does trial NCT00576095 study?
This clinical trial studies the following conditions: Depression, Depressive Disorder, Major, Psychotic Disorders.
Who is sponsoring clinical trial NCT00576095?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00576095 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00576095's enrollment target sits among peer trials
73 397th of 679 higher than 279 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Depression and Driving
RECRUITING
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia